A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care

Carcinoma, Hepatocellular Clinical Trial

Official title:

A Phase 1/2 Study of DENSPM (N1, N11-diethylnorspermine) in Patients With Unresectable Hepatocellular Carcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00081900
• Other study ID #: GD3-165-101
• Status: Terminated
• Phase: Phase 1/Phase 2
• First received: April 26, 2004
• Last updated: April 9, 2015
• Start date: March 2004
• Est. completion date: November 2007

Study information

• Verified date: April 2015
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Approximately 18-45 patients with Hepatocellular Carcinoma (HCC) will be treated with DENSPM at approximately 5 centers in the United States. First, we will be trying to determine the highest dose that can be given safely and is well tolerated (this is called the maximally tolerated dose, or the MTD, for short). Once that is established, we will enroll additional patients to learn more about potential side effects and to see whether DENSPM can slow the growth of HCC tumors. We also want to learn about the safety of DENSPM. Many medications used to treat cancer cause side effects (discomforts or illness). In this study, we want to understand what side effects occur in patients with HCC who are treated with DENSPM.Study was terminated after initial assessment of insufficient data to support clinical benefit in this population.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 38
• Est. completion date: November 2007
• Est. primary completion date: July 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically proven HCC, or if the patient is not a medically appropriate candidate for biopsy, then all of the following criteria must be met: A.History of cirrhosis or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV)infection. B.A focal liver lesion = 3 cm on CT or MRI with arterial hypervascularization. C.Confirmation of the liver lesion by a second imaging modality (US/ CT/ MRI).D.AFP =1000 ng/ml, or = 4000 ng/ml if Hepatitis B surface Ag positive.

• For recurrent HCC, radiographic evidence of progression.

• Not appropriate for curative therapy (surgical resection) or refuses potentially curative therapy

• Measurable disease, defined as having at least one measurable intrahepatic tumor lesion (using Response Criteria in Solid Tumors [RECIST]). Prior therapy is acceptable only if there is documented progression of the selected measurable lesion(s) following completion of the therapy.

• Required laboratory values

• Renal function: serum creatinine =1.2mg/dL Hematologic function: leukocyte count =1,500/mm3, platelet count =50,000/mm3 Hepatic function: transaminases =5x upper limit normal (ULN), albumin =2.0g/dL, total bilirubin =3.5mg/dL Sodium: =130mEq/L

• Karnofsky Performance Status of = 60%

• CLIP Score = 3

• If female and of childbearing potential, must use an effective method of contraception

• Willing and able to provide written informed consent

Exclusion Criteria:

• Has received localized therapy (e.g., radiotherapy, RFA, injection therapy, or chemoembolization)within 6 weeks prior to treatment, Day1. Prior local lesion-specific radiotherapy is acceptable only if the treated lesion(s) is/are not the only source of measurable disease or there is documented progression of the treated lesion(s) following completion of the therapy.

• Has received any other systemic therapy for HCC within 3 weeks prior to treatment, Day 1. Prior therapy is acceptable only if there is documented progression following completion of the therapy.

• Has received another investigational therapy within 30 days prior to study entry

• Has any unstable serious or life-threatening medical condition, other than HCC (e.g., unstable angina, other cancer diagnosis with the exception of basal cell carcinoma, or patients with prior malignancy except for adequately treated basal cell carcinoma(s), in situ cervical cancer, or other cancer for which the patient has been disease-free for five or more years)

• Newly noted clinically significant electrocardiogram (ECG) abnormality

• Clinically significant abnormal laboratory result that is not consistent with patient's clinical course

• Active gastrointestinal bleeding resulting in clinically significant hemodynamic changes or a reduction in hemoglobin.

• Active inflammatory bowel disease (IBD) and/or active gastric or duodenal ulcer disease

• Has a history of central nervous system (CNS) metastases, seizure disorder or neurological exam finding suggestive of CNS metastases

• Has Stage B or C liver cirrhosis according to Child-Pugh-Turcotte Classification

• Has ascites refractory to diuretic therapy

• Has any contraindication for MRI procedure

• If female of childbearing potential, has a positive serum HCG

• If female, is lactating

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular

Intervention

Drug:
• DENSPM )
Each patient will receive DENSPM at an initial dose of 30mg/m^2, then escalating to 120mg/m^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Dana Farber Partners Cancer Care	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	University of Virginia	Charlottesville	Virginia
United States	University of Illinois- Chicago	Chicago	Illinois
United States	Mary Crowley Medical Research Center	Dallas	Texas
United States	Vanderbilt University School of Medicine	Nashville	Tennessee
United States	McGuire VA Medical Center	Richmond	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Genzyme, a Sanofi Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the overall safety profile of DENSPM intravenous infusion in patients with unresectable HCC.		8 months	Yes
Primary	To establish the MTD and dose limiting toxicities of DENSPM intravenous infusion in patients with unresectable HCC.		8 months	No
Secondary	To evaluate antitumor response as measured by progression free survival when DENSPM is administered for up to eight 28 day cycles in patients with advanced HCC.		8 months	No
Secondary	To evaluate the pharmacokinetics of DENSPM in plasma and HCC tissue in patients unresectable HCC.		8 months	No